Table 1 The baseline characteristics of 107 patients with long-term outcomes

Female, No. (%)

27 (45.0)

33 (70.2)

0.009

Age, years

59.88 ± 10.35

58.06 ± 10.63

0.347

BMI, kg/m²

22.27 ± 3.28

22.86 ± 3.03

0.463

History of hemoptysis ≥10 years, No. (%)

31 (51.7)

20 (42.6)

0.349

Extent of hemoptysis, No. (%)

<  0.001

 < 100 mL

19 (31.7)

34 (72.3)

<  0.001

 100–300 mL

26 (43.3)

11 (23.4)

0.031

 ≥ 300 mL

15 (25.0)

2 (4.3)

0.004

Smoke, No. (%)

12 (20.0)

7 (14.9)

0.493

Hypertension, No. (%)

13 (21.7)

10 (21.3)

0.961

Diabetes, No. (%)

4 (6.7)

2 (4.3)

0.693

Admission SBP, mmHg

124 (115–130)

128 (117–138)

0.464

Hemoglobin, g/L

123.03 ± 18.78

125.60 ± 16.58

0.278

PLT, *10⁹/L

185.75 ± 59.64

189.53 ± 51.81

0.770

WBC, *10⁹/L

7.97 ± 2.73

6.46 ± 1.91

0.002

Number of lung segments involved

4 (2–7)

5 (2–8)

0.578

Bronchial dilatation severity score

1.8 (1.0–2.7)

2.1 (1.7–2.6)

0.072

Bronchial wall thickening severity score

2.4 (1.8–3.0)

2.4 (2.0–3.0)

0.765

Bronchiectasis type, No. (%)

0.019

 Columnar

17 (28.3)

5 (10.6)

0.025

 Varicose

21 (35.0)

13 (27.7)

0.418

 Cystic

22 (36.7)

29 (61.7)

0.01

In-hospital days

5 (4.0–7.8)

7 (6.0–9.0)

0.003

Hemoptysis recurrence, No. (%)

21 (35.0)

45 (95.7)

<  0.001

Follow-up period, months

31.2 (21.4–55.5)

27.7 (8.1–48.5)

–